Treatment Outcome and Prognostic factors of Glioblastoma Multiforme

Background and Aim: Background and aim: This is a retrospective study of 
Egyptian patients with glioblastoma multiforme who had undergone biopsy and 
or surgical resection and radiation to identify clinical, pathological, radiological 
and to asses treatment outcome (overall survival OS and progression free 
survival PFS).
Patients and methods: two hundreds & ten patients with glioblastoma 
multiforme data was collected and recorded in a personal database from paper 
and electronic medical records and variables were analyzed.
Results: The median overall survival time was 9 months, while the median time 
to progression was 6 months. Multivariate analysis revealed that ECOG PS, 
absence of adjuvant temozolamide, tumor site, were statistically significant 
independent predictors for overall survival OS and progression free survival 
PFS. Hazard ratios & confidence intervals of OS were 1.72 (1.16-2.56), 1.94 
(1.41-2.67), 1.43 (1.05-1.94) respectively, while for PFS, Hazard ratios & 
confidence intervals were 2.1 (1.5-2.9), 1.4 (1.05-1.9), and 1.44 (0.98-2.13), 
respectively.
Conclusion: Glioblastoma multiforme still an aggressive disease with short PFS 
and OS. Good performance status, TMZ chemotherapy and tumor location were 
significant prognostic factors.